Sonoma Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

8. Stock-Based Compensation (Details - Allocated Share-Based Compensation Expense) (USD $)	3 Months Ended		9 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Total stock-based compensation	$ 447,000	$ 291,000	$ 1,354,000	$ 772,000
Cost of revenues [Member]
Total stock-based compensation	58,000	29,000	180,000	84,000
Research and development [Member]
Total stock-based compensation	82,000	45,000	260,000	122,000
Selling, general and administrative [Member]
Total stock-based compensation	$ 307,000	$ 217,000	$ 914,000	$ 566,000